Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University Medical Center Utrecht

http://www.umcutrecht.nl/en/1

Latest From University Medical Center Utrecht

Venture Funding Deals: CNS Plays Are Attracting Investment

Polyneuron, Synerkine, Harmony, EIP Pharma and AITI Life Sciences all raised cash in recent weeks to tackle various conditions involving the nervous system. More recent venture funding deals... 

Financing StartUps and SMEs

Finance Watch: Arteaus Comes Full Circle As Investors Monetize Emgality Royalties

Arteaus sells royalty stream from Lilly's Emgality giving investors a $260m payday. Also, Pfizer spin-out SpringWorks nabs another $125m, Arch Oncology and Prevail Therapeutics close $50m Series B rounds, and Karuna's recent financing grows to $80m.

Financing StartUps and SMEs

Recent Financings of Private Companies (12/2007)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

The Heat is on for First Circle Medical

Many scientists and physicians believe in the healing power of heat, but to date, there have been no major commercial successes in hyperthermia. Hyperthermia companies suffer from the field's checkered past: a wave of commercial hyperthermia flameouts in the 1980's means that many investors won't give hyperthermia companies a second glance. First Circle Medical's challenge is to win over skeptical investors and clinicians as it pursues a new device market for hepatitis C. There it aims to offer a side effect free alternative to drugs for a deadly and prevalent disease with few therapeutic options, or, at the very least, a procedure that will potentially boost the efficacy of drugs. But as the first and only player in a new field, and in light of the prejudice against hyperthermia devices that many share, First Circle has to create a base of rigorous scientific data from scratch; indeed, it has to bear the burden of doing everything right.

Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • Academic and Research Institutions
UsernamePublicRestriction

Register